Patent application number | Description | Published |
20080221200 | Combination of Organic Compounds - The present invention relates to a combination, such as a combined preparation or pharmaceutical composition, respectively, comprising of a DPP IV inhibitor or a pharmaceutically acceptable salt thereof and comprising at least one immunosuppressive or immunomodulator agent, or a pharmaceutically acceptable salt thereof. | 09-11-2008 |
20080300171 | Use of Dpp-IV Inhibitor to Reduce Hypoglycemic Events - The invention relates to a method to reduce the hypoglycemic events, especially sever hypoglycemic events resulting from insulin treatment, wherein the patient is treated with a Dipeptidyl peptidase IV inhibitor (DPP-IV inhibitor) or a pharmaceutically acceptable salt thereof. | 12-04-2008 |
20090017015 | Dpp-iv inhibitors for treating neurodegeneration and cognitive disorders - The invention relates to the use of a Dipeptidyl peptidase IV inhibitor (DPP-IV inhibitor) or a pharmaceutically acceptable salt thereof for the prevention, delay of progression or the treatment of neurodegenerative disorders, cognitive disorders and for improving memory (both short term and long term) and learning ability. | 01-15-2009 |
20090253752 | COMBINATION OF DPP-IV INHIBITOR, PPAR ANTIDIABETIC AND METMORFIN - The invention relates to a combination, such as a combined preparation or pharmaceutical composition, respectively, which comprises;
| 10-08-2009 |
20100016387 | METHOD OF TREATMENT - Method of preventing or treating myocardial ischemia by inhibiting DGAT1 enzyme with a DGAT1 inhibitor compound. | 01-21-2010 |
20100160408 | VILDAGLIPTIN FOR TREATING GENERAL PERIPHERAL NEUROPATHIES - The present invention is directed to use of a Dipeptidyl peptidase IV inhibitor for treating general peripheral neuropathies, in particular, the present invention provides a method for the prevention, delay of progression, or the treatment of general peripheral neuropathies in a patient in need thereof, by administering an effective amount of vildagliptin or a pharmaceutically acceptable salt thereof. | 06-24-2010 |
20110245317 | USE OF ORGANIC COMPOUNDS - This application is directed to methods for improving glucose control by administering metformin in combination with a DPP-IV inhibitor to a patient in need thereof, in an amount sufficient to control the glucose level over an extended period of time. | 10-06-2011 |
20110301172 | COMBINATION OF DPP-IV INHIBITOR, PPAR ANTIDIABETIC AND METMORFORMIN - The invention relates to a combination, such as a combined preparation or pharmaceutical composition, respectively, which comprises;
| 12-08-2011 |
20120149639 | USE OF A DPP-IV INHIBITOR TO REDUCE HYPOGLYCEMIC EVENTS - The invention relates to a method to reduce the hypoglycemic events, especially severe hypoglycemic events resulting from insulin treatment, wherein the patient is treated with a Dipeptidyl peptidase IV inhibitor (DPP-IV inhibitor) or a pharmaceutically acceptable salt thereof. | 06-14-2012 |